Evidence map›Paper›PMID 36533153›Full record

ArticleVirus evolution2022

The origins and molecular evolution of SARS-CoV-2 lineage B.1.1.7 in the UK.

Verity Hill, Louis Du Plessis, Thomas P Peacock, Dinesh Aggarwal, Rachel Colquhoun, Alesandro M Carabelli, Nicholas Ellaby, Eileen Gallagher, Natalie Groves, Ben Jackson and 19 more

Erratum issuedAbstract read
In one paragraph

Article in Virus evolution, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 101 papers.

0numbers the graph read from it
0cells of the map it votes in
101citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

101 citing papers in PubMed.

  1. Viral syncytia evolve to resist interferon.Nature communications · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Review
  19. Article
  20. Article

41 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

29 authors.

Verity HillAshworth Laboratories, Institute of Evolutionary Biology, University of Edinburgh, Edinburgh EH9 3FL, UK.ORCID https://orcid.org/0000-0002-3509-8146
Louis Du PlessisDepartment of Biology, University of Oxford, 11a Mansfield Rd, Oxford OX1 3SZ, UK.
Thomas P PeacockDepartment of Infectious Disease, Imperial College London, London W2 1PG, UK.
Dinesh AggarwalWellcome Sanger Institute, Wellcome Genome Campus, Hinxton CB10 1RQ, UK.
Rachel ColquhounAshworth Laboratories, Institute of Evolutionary Biology, University of Edinburgh, Edinburgh EH9 3FL, UK.ORCID https://orcid.org/0000-0002-5577-9897
Alesandro M CarabelliDepartment of Medicine, University of Cambridge, Cambridge, UK.ORCID https://orcid.org/0000-0003-3625-4021
Nicholas EllabyUK Health Security Agency, 61 Colindale Avenue, London NW9 5EQ, UK.
Eileen GallagherUK Health Security Agency, 61 Colindale Avenue, London NW9 5EQ, UK.
Natalie GrovesUK Health Security Agency, 61 Colindale Avenue, London NW9 5EQ, UK.
Ben JacksonAshworth Laboratories, Institute of Evolutionary Biology, University of Edinburgh, Edinburgh EH9 3FL, UK.ORCID https://orcid.org/0000-0002-9981-0649
J T McCroneAshworth Laboratories, Institute of Evolutionary Biology, University of Edinburgh, Edinburgh EH9 3FL, UK.ORCID https://orcid.org/0000-0002-9846-8917
Áine O'TooleAshworth Laboratories, Institute of Evolutionary Biology, University of Edinburgh, Edinburgh EH9 3FL, UK.ORCID https://orcid.org/0000-0001-8083-474X
Anna PriceSchool of Biosciences, The Sir Martin Evans Building, Cardiff University, Cardiff CF10 AX, UK.
Theo SandersonWellcome Sanger Institute, Wellcome Genome Campus, Hinxton CB10 1RQ, UK.
Emily ScherAshworth Laboratories, Institute of Evolutionary Biology, University of Edinburgh, Edinburgh EH9 3FL, UK.ORCID https://orcid.org/0000-0002-5401-5879
Joel SouthgateSchool of Biosciences, The Sir Martin Evans Building, Cardiff University, Cardiff CF10 AX, UK.
Erik VolzMRC Unit for Global Infectious Disease Analysis, School of Public Health, Imperial College London, London, UK.ORCID https://orcid.org/0000-0001-6268-8937
Wendy S BarclayDepartment of Infectious Disease, Imperial College London, London W2 1PG, UK.
Jeffrey C BarrettWellcome Sanger Institute, Wellcome Genome Campus, Hinxton CB10 1RQ, UK.
Meera ChandUK Health Security Agency, 61 Colindale Avenue, London NW9 5EQ, UK.
Thomas ConnorSchool of Biosciences, The Sir Martin Evans Building, Cardiff University, Cardiff CF10 AX, UK.ORCID https://orcid.org/0000-0003-2394-6504
Ian GoodfellowDepartment of Pathology, University of Cambridge, Cambridge CB2 1QP, UK.
Ravindra K GuptaDepartment of Medicine, University of Cambridge, Cambridge, UK.
Ewan M HarrisonWellcome Sanger Institute, Wellcome Genome Campus, Hinxton CB10 1RQ, UK.
Nicholas LomanInstitute of Microbiology and Infection, University of Birmingham, Birmingham B15 2TT, UK.
Richard MyersUK Health Security Agency, 61 Colindale Avenue, London NW9 5EQ, UK.
David L RobertsonMRC-University of Glasgow Centre for Virus Research, 464 Bearsden Road, Glasgow G61 1QH, Scotland, UK.ORCID https://orcid.org/0000-0001-6338-0221
Oliver G PybusDepartment of Biology, University of Oxford, 11a Mansfield Rd, Oxford OX1 3SZ, UK.ORCID https://orcid.org/0000-0002-8797-2667
Andrew RambautAshworth Laboratories, Institute of Evolutionary Biology, University of Edinburgh, Edinburgh EH9 3FL, UK.ORCID https://orcid.org/0000-0003-4337-3707

Funding

Biotechnology and Biological Sciences Research Council BB/M010996/1European Research Council 725422Medical Research Council MC_PC_19026Medical Research Council MC_PC_19027Medical Research Council MR/R015600/1Medical Research Council MR/W005611/1Wellcome Trust
6 · The paper itself

Abstract

The first SARS-CoV-2 variant of concern (VOC) to be designated was lineage B.1.1.7, later labelled by the World Health Organization as Alpha. Originating in early autumn but discovered in December 2020, it spread rapidly and caused large waves of infections worldwide. The Alpha variant is notable for being defined by a long ancestral phylogenetic branch with an increased evolutionary rate, along which only two sequences have been sampled. Alpha genomes comprise a well-supported monophyletic clade within which the evolutionary rate is typical of SARS-CoV-2. The Alpha epidemic continued to grow despite the continued restrictions on social mixing across the UK and the imposition of new restrictions, in particular, the English national lockdown in November 2020. While these interventions succeeded in reducing the absolute number of cases, the impact of these non-pharmaceutical interventions was predominantly to drive the decline of the SARS-CoV-2 lineages that preceded Alpha. We investigate the only two sampled sequences that fall on the branch ancestral to Alpha. We find that one is likely to be a true intermediate sequence, providing information about the order of mutational events that led to Alpha. We explore alternate hypotheses that can explain how Alpha acquired a large number of mutations yet remained largely unobserved in a region of high genomic surveillance: an under-sampled geographical location, a non-human animal population, or a chronically infected individual. We conclude that the latter provides the best explanation of the observed behaviour and dynamics of the variant, although the individual need not be immunocompromised, as persistently infected immunocompetent hosts also display a higher within-host rate of evolution. Finally, we compare the ancestral branches and mutation profiles of other VOCs and find that Delta appears to be an outlier both in terms of the genomic locations of its defining mutations and a lack of the rapid evolutionary rate on its ancestral branch. As new variants, such as Omicron, continue to evolve (potentially through similar mechanisms), it remains important to investigate the origins of other variants to identify ways to potentially disrupt their evolution and emergence.

Indexed as

SARS-COV-2variants of concernVirus evolutionWithin-host evolution

Identifiers

PMID36533153
PMCPMC9752794

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.